Real‐world observations of GLP‐1 receptor agonists and SGLT‐2 inhibitors as potential treatments for Alzheimer's disease
Glucagon-like peptide-1 (GLP-1) receptor agonists are significantly associated with a reduced risk of Alzheimer's disease (AD) compared to dipeptidyl peptidase-4 (DPP-4) inhibitors. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are significantly associated with a reduced risk of AD compared to dipeptidyl peptidase-4 (DPP-4) inhibitors. Two GLP-1 receptor agonists (liraglutide and semaglutide) and three SGLT-2 inhibitors (dapagliflozin, canagliflozin, and empagliflozin) are associated with a reduced risk of AD in drug-specific sensitivity analyses.
Authors
- Anna Sun (ORCID: https://orcid.org/0009-0007-6467-0563)
- James B. Leverenz (ORCID: https://orcid.org/0000-0002-0896-0749)
- Zhimin Fu (ORCID: https://orcid.org/0000-0001-5424-6696)
- Andrew A. Pieper (ORCID: https://orcid.org/0000-0001-6299-6577)
- Chengsheng Mao (ORCID: https://orcid.org/0000-0002-1515-9626)
- Yuedi Yang (ORCID: https://orcid.org/0000-0003-3355-4723)
- Yuan Luo (ORCID: https://orcid.org/0000-0003-0195-7456)
- Pengyue Zhang (ORCID: https://orcid.org/0000-0002-9148-5589)
- Feixiong Cheng
- Jeffrey Cummings
- Yuan Hou
- Tousi Babak
Institutions
- Northwestern University (US)
- University of Nevada, Las Vegas (US)
- Lou Ruvo Brain Institute (US)
- Cleveland Clinic Lerner College of Medicine (US)
- University Hospitals Cleveland Medical Center (US)
- Geriatric Research Education and Clinical Center (US)
- Louis Stokes Cleveland VA Medical Center (US)
- Cleveland Clinic Akron General (US)
- Indiana University Indianapolis (US)
- Indiana University – Purdue University Indianapolis (US)
- Case Western Reserve University (US)
- Northeast Ohio Medical University (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1002/alz.70639
- Citations
- 10
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 12.95
Funders
- Alzheimer's Association
- American Heart Association
- Alzheimer's Drug Discovery Foundation
- Case Western Reserve University
- National Institutes of Health
- National Institute on Aging
- National Institute of General Medical Sciences
- National Institute of Neurological Disorders and Stroke
- U.S. National Library of Medicine